Literature DB >> 15724723

The seroepidemiology of Bordetella pertussis infection in Western Europe.

R G Pebody1, N J Gay, A Giammanco, S Baron, J Schellekens, A Tischer, R M Olander, N J Andrews, W J Edmunds, H Lecoeur, D Lévy-Bruhl, P A C Maple, H de Melker, A Nardone, M C Rota, S Salmaso, M A E Conyn-van Spaendonck, S Swidsinski, E Miller.   

Abstract

High titres of pertussis toxin (PT) antibody have been shown to be predictive of recent infection with Bordetella pertussis. The seroprevalence of standardized anti-PT antibody was determined in six Western European countries between 1994 and 1998 and related to historical surveillance and vaccine programme data. Standardized anti-PT titres were calculated for a series of whole-cell and acellular pertussis vaccine trials. For the serological surveys, high-titre sera (> 125 units/ml) were distributed throughout all age groups in both high- (> 90%) and low-coverage (< 90%) countries. High-titre sera were more likely in infants in countries using high-titre-producing vaccines in their primary programme (Italy, 11.5%; Western Germany, 13.3%; France, 4.3%; Eastern Germany, 4.0%) compared to other countries (The Netherlands, 0.5%; Finland, 0%). Recent infection was significantly more likely in adolescents (10-19 years old) and adults in high-coverage countries (Finland, The Netherlands, France, East Germany), whereas infection was more likely in children (3-9 years old) than adolescents in low-coverage (< 90%; Italy, West Germany, United Kingdom) countries. The impact and role of programmatic changes introduced after these surveys aimed at protecting infants from severe disease by accelerating the primary schedule or vaccinating older children and adolescents with booster doses can be evaluated with this approach.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15724723      PMCID: PMC2870234          DOI: 10.1017/s0950268804003012

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  41 in total

1.  Seroprevalence of pertussis among Danish patients with cough of unknown etiology.

Authors:  Tine Dalby; Zitta B Harboe; Karen Angeliki Krogfelt
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

2.  Imperfect vaccine-induced immunity and whooping cough transmission to infants.

Authors:  Jennie Lavine; Hélène Broutin; Eric T Harvill; Ottar N Bjørnstad
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

3.  Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy.

Authors:  G Gabutti; M Bergamini; P Bonanni; M Guido; D Fenoglio; A Giammanco; L Sindoni; C Zotti; V Boddi; F Bamfi; R Severini; A Bechini; S Boccalini; P Crovari
Journal:  Epidemiol Infect       Date:  2008-01-16       Impact factor: 2.451

4.  Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure.

Authors:  Jennie S Lavine; Aaron A King; Ottar N Bjørnstad
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

5.  Hospitalizations for pertussis in Italy, 1999-2009: analysis of the hospital discharge database.

Authors:  Giovanni Gabutti; Maria Cristina Rota; Bernardo Bonato; Roberta Pirani; Giuliana Turlà; Alessandro Cucchi; Alessandra Cavallaro
Journal:  Eur J Pediatr       Date:  2012-07-13       Impact factor: 3.183

6.  The seroepidemiology of pertussis in Australia during an epidemic period.

Authors:  M Cagney; C R MacIntyre; P McIntyre; M Puech; A Giammanco
Journal:  Epidemiol Infect       Date:  2006-05-11       Impact factor: 2.451

Review 7.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  Seroprevalence study of B. pertussis infection in health care workers in Catalonia, Spain.

Authors:  Luis Urbiztondo; Sonia Broner; Josep Costa; Laura Rocamora; José M Bayas; Magda Campins; Maria Esteve; Eva Borras; Angela Domínguez; The Working Group For The Study Of The Immune Status In Health Care
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 9.  Resolving pertussis immunity and vaccine effectiveness using incidence time series.

Authors:  Jennie S Lavine; Pejman Rohani
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

10.  Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries.

Authors:  Mirjam Kretzschmar; Peter F M Teunis; Richard G Pebody
Journal:  PLoS Med       Date:  2010-06-22       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.